CLINICAL—LIVER
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
Gideon M. Hirschfield,1Andrew Mason,2Velimir Luketic,3,4Keith Lindor,5,6Stuart C. Gordon,7Marlyn Mayo,8Kris V. Kowdley,9Catherine Vincent,10Henry C. Bodhenheimer Jr,11,12Albert Parés,13Michael Trauner,14Hanns-Ulrich Marschall,15Luciano Adorini,16
Cathi Sciacca,16Tessa Beecher-Jones,16Erin Castelloe,16Olaf B?hm,17and David Shapiro16
1Centre for Liver Research, NIHR Birmingham Liver Biomedical Research Unit, University of Birmingham, Birmingham, UK;
2Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada;3Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University School of Medicine, Richmond, Virginia;4McGuire Research Institute, McGuire VA Medical Center, Richmond, VA;5Division of Gastroenterology and Hepatology, Mayo Medical School, Rochester, Minnesota;6School for the Science of Health Care Delivery, Arizona State University, Phoenix, Arizona;7Division of Hepatology, Henry Ford Health Systems, Detroit, Michigan;8Division of Digestive and Liver Diseases, University of Texas, Southwestern Medical Center, Dallas, Texas;9Digestive Disease Institute, Virginia Mason Medical Center, Seattle, Washington;10Department of Hepatology, Hopital Saint-Luc/CHUM Montreal, Canada;11Department of Medicine, Mount Sinai School of Medicine, New York, New York;12Division of Digestive Diseases, Beth Israel Medical Center, New York, New York;13Liver Unit, Hospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain;14Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Austria;15Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;16Intercept Pharmaceuticals, San Diego, California; and17FGK Clinical Research, Munich, Germany。